Log in
NASDAQ:AEZS

Aeterna Zentaris Stock Forecast, Price & News

$0.44
+0.05 (+12.78 %)
(As of 12/2/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.40
Now: $0.44
$0.45
50-Day Range
$0.30
MA: $0.36
$0.42
52-Week Range
$0.29
Now: $0.44
$1.54
Volume6.79 million shs
Average Volume2.04 million shs
Market Capitalization$27.66 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
CUSIPN/A
Phone49-6942-6020
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$530,000.00
Book Value$0.24 per share

Profitability

Net Income$-6,040,000.00
Net Margins-369.10%

Miscellaneous

Market Cap$27.66 million
Next Earnings Date3/29/2021 (Estimated)
OptionableOptionable
$0.44
+0.05 (+12.78 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aeterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

How has Aeterna Zentaris' stock been impacted by Coronavirus (COVID-19)?

Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AEZS shares have decreased by 35.1% and is now trading at $0.4413.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Aeterna Zentaris?

Wall Street analysts have given Aeterna Zentaris a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aeterna Zentaris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aeterna Zentaris' next earnings date?

Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aeterna Zentaris
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.13 million for the quarter. Aeterna Zentaris had a negative net margin of 369.10% and a negative return on equity of 125.54%.
View Aeterna Zentaris' earnings history
.

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 772,700 shares, a decline of 19.8% from the October 31st total of 962,900 shares. Based on an average trading volume of 2,300,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.3% of the company's shares are short sold.
View Aeterna Zentaris' Short Interest
.

Who are some of Aeterna Zentaris' key competitors?

What other stocks do shareholders of Aeterna Zentaris own?

Who are Aeterna Zentaris' key executives?

Aeterna Zentaris' management team includes the following people:
  • Dr. Klaus Paulini Ph.D., Pres, CEO & Director
  • Ms. Leslie Auld C.A., CPA, M.B.A., MBA, CPA, CA, Sr. VP & CFO
  • Dr. Nicola Ammer M.D., Chief Medical Officer & VP of Clinical Devel.
  • Dr. Matthias Gerlach, VP of Manufacturing & Supply Chain
  • Mr. Olaf Althaus, GM & MD
  • Dr. Eckhard G. Guenther Ph.D., VP of Bus. Devel. & Alliance Management and Managing Director AEZS Germany
  • Ms. Amélie Métivier, Assistant Sec.

What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (1.79%) and Wedbush Securities Inc. (0.15%).

Which major investors are buying Aeterna Zentaris stock?

AEZS stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, and Wedbush Securities Inc..

How do I buy shares of Aeterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $0.44.

How big of a company is Aeterna Zentaris?

Aeterna Zentaris has a market capitalization of $27.66 million and generates $530,000.00 in revenue each year.

What is Aeterna Zentaris' official website?

The official website for Aeterna Zentaris is www.zentaris.com.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 49-6942-6020 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.